Literature DB >> 19357166

Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression.

Corey Smith1, Leone Beagley, Rajiv Khanna.   

Abstract

Latent membrane antigen 1 and -2 (LMP-1/2)-specific CD8(+) T cells from newly diagnosed and relapsed Hodgkin's lymphoma (HL) patients display a selective functional impairment. In contrast, CD8(+) T cells specific for Epstein-Barr virus (EBV) nuclear proteins and lytic antigens retain normal T-cell function. Reversion to a dysfunctional phenotype of LMP-1/2-specific T cells is coincident with the regression of HL. To delineate the potential basis for this differential susceptibility for the loss of function, we have carried out a comprehensive functional analysis of EBV-specific T cells using ex vivo multiparametric flow cytometry in combination with assessment of antigen-driven proliferative potential. This analysis revealed that LMP-1/2-specific T cells from healthy virus carriers display a deficient polyfunctional profile compared to that of T cells specific for epitopes derived from EBV nuclear proteins and lytic antigens. Furthermore, LMP-specific T-cells are highly susceptible to galectin-1-mediated immunosuppression and are less likely to degranulate following exposure to cognate peptide epitopes and poorly recognized endogenously processed epitopes from virus-infected B cells. More importantly, ex vivo stimulation of these T cells with an adenoviral vector encoding multiple minimal CD8(+) T-cell epitopes as a polyepitope, in combination with a gammaC cytokine, interleukin-2, restored polyfunctionality and shielded these cells from the inhibitory effects of galectin-1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19357166      PMCID: PMC2687380          DOI: 10.1128/JVI.00239-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

Review 1.  Epstein-Barr virus: exploiting the immune system.

Authors:  D A Thorley-Lawson
Journal:  Nat Rev Immunol       Date:  2001-10       Impact factor: 53.106

Review 2.  Replication licensing of the EBV oriP minichromosome.

Authors:  K Hirai; M Shirakata
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

3.  Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells.

Authors:  K Yamaoka; K Mishima; Y Nagashima; A Asai; Y Sanai; T Kirino
Journal:  J Neurosci Res       Date:  2000-03-15       Impact factor: 4.164

Review 4.  Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases.

Authors:  R Khanna; S R Burrows
Journal:  Annu Rev Microbiol       Date:  2000       Impact factor: 15.500

5.  Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells.

Authors:  Gamal Badr; Nathalie Bédard; Mohamed S Abdel-Hakeem; Lydie Trautmann; Bernard Willems; Jean-Pierre Villeneuve; Elias K Haddad; Rafick P Sékaly; Julie Bruneau; Naglaa H Shoukry
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

Review 6.  How regulatory T cells work.

Authors:  Dario A A Vignali; Lauren W Collison; Creg J Workman
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

7.  Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients.

Authors:  F A van den Brûle; D Waltregny; V Castronovo
Journal:  J Pathol       Date:  2001-01       Impact factor: 7.996

8.  Magnitude and quality of vaccine-elicited T-cell responses in the control of immunodeficiency virus replication in rhesus monkeys.

Authors:  Yue Sun; Sampa Santra; Jörn E Schmitz; Mario Roederer; Norman L Letvin
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

9.  AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.

Authors:  Scott J Rodig; Jing Ouyang; Przemyslaw Juszczynski; Treeve Currie; Kenneth Law; Donna S Neuberg; Gabriel A Rabinovich; Margaret A Shipp; Jeffery L Kutok
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

10.  Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells.

Authors:  Jihène Klibi; Toshiro Niki; Alexander Riedel; Catherine Pioche-Durieu; Sylvie Souquere; Eric Rubinstein; Sylvestre Le Moulec; Sylvestre L E Moulec; Joël Guigay; Mitsuomi Hirashima; Fethi Guemira; Dinesh Adhikary; Josef Mautner; Pierre Busson
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

View more
  15 in total

1.  CD8 T cell exhaustion in human visceral leishmaniasis.

Authors:  Shalini Gautam; Rajiv Kumar; Neetu Singh; Abhishek Kumar Singh; Madhukar Rai; David Sacks; Shyam Sundar; Susanne Nylén
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

2.  Cytomegalovirus-Responsive CD8+ T Cells Expand After Solid Organ Transplantation in the Absence of CMV Disease.

Authors:  L E Higdon; J Trofe-Clark; S Liu; K B Margulies; M K Sahoo; E Blumberg; B A Pinsky; J S Maltzman
Journal:  Am J Transplant       Date:  2017-03-13       Impact factor: 8.086

Review 3.  Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine.

Authors:  Corey Smith; Rajiv Khanna
Journal:  Immunol Cell Biol       Date:  2017-01-10       Impact factor: 5.126

4.  Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.

Authors:  Raymond J Ning; Xue Q Xu; Kwok H Chan; Alan K S Chiang
Journal:  Immunology       Date:  2011-10       Impact factor: 7.397

5.  Functional Consequences of Memory Inflation after Solid Organ Transplantation.

Authors:  Lauren E Higdon; Steven Schaffert; Rachel H Cohen; Maria E Montez-Rath; Marc Lucia; Naresha Saligrama; Kenneth B Margulies; Olivia M Martinez; Jane C Tan; Mark M Davis; Purvesh Khatri; Jonathan S Maltzman
Journal:  J Immunol       Date:  2021-09-22       Impact factor: 5.426

6.  Restriction of Human Cytomegalovirus Infection by Galectin-9.

Authors:  Allison Abendroth; Brian P McSharry; Barry Slobedman; Emily A Machala; Selmir Avdic; Lauren Stern; Dirk M Zajonc; Chris A Benedict; Emily Blyth; David J Gottlieb
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

7.  Spatiotemporal regulation of galectin-1-induced T-cell death in lamina propria from Crohn's disease and ulcerative colitis patients.

Authors:  Rodrigo Papa-Gobbi; Cecilia I Muglia; Andrés Rocca; Renata Curciarello; Alicia M Sambuelli; Martín Yantorno; Gustavo Correa; Luciano G Morosi; Antonio Di Sabatino; Paolo Biancheri; Thomas T MacDonald; Marta A Toscano; Karina V Mariño; Gabriel A Rabinovich; Guillermo H Docena
Journal:  Apoptosis       Date:  2021-05-12       Impact factor: 4.677

8.  A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.

Authors:  Graham S Taylor; Hui Jia; Kevin Harrington; Lip Wai Lee; James Turner; Kristin Ladell; David A Price; Manjit Tanday; Jen Matthews; Claudia Roberts; Ceri Edwards; Lesley McGuigan; Andrew Hartley; Steve Wilson; Edwin P Hui; Anthony T C Chan; Alan B Rickinson; Neil M Steven
Journal:  Clin Cancer Res       Date:  2014-08-14       Impact factor: 12.531

9.  Evaluating cellular polyfunctionality with a novel polyfunctionality index.

Authors:  Martin Larsen; Delphine Sauce; Laurent Arnaud; Solène Fastenackels; Victor Appay; Guy Gorochov
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

10.  A new approach for cellular immunotherapy of nasopharyngeal carcinoma.

Authors:  Corey Smith; Rajiv Khanna
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.